Mesoporous Silica Supraparticles for Sustained Inner-Ear Drug Delivery

Y Wang; JW Maina; F Caruso; AK Wise; RK Shepherd; J Tan

Journal article

Mesoporous Silica Supraparticles for Sustained Inner-Ear Drug Delivery

Y Wang, JW Maina, F Caruso, AK Wise, RK Shepherd, J Tan

Small | Wiley | Published : 2014

DOI: 10.1002/smll.201401767

Download PDF

Abstract

Mesoporous silica supraparticles (MS-SPs) are prepared via self-assembly of mesoporous silica nanoparticles under capillary force action in confined droplets. The MS-SPs are effective carriers for sustained drug delivery. Animal studies show that these particles are suitable for chronic intracochlear implantation, and neurotrophins released from the MS-SPs can efficiently rescue primary auditory neurons in an in vivo sensorineural hearing loss model.

University of Melbourne Researchers

Frank Caruso Author

Andrew Wise Author

Robert Shepherd Author

Related Projects (3)

ENGINEERING MATERIALS FOR ADVANCES IN NANOMEDICINE

Nanomedicine is one of the fastest growing areas in nanotechnology. This project will develop next-generation particle systems with engineer..

NANOPARTICLE BASED NEUROTROPHIN DELIVERY TO PROMOTE DIRECTED NEURITE GROWTH AND AUDITORY NERVE RESCUE FOLLOWING DEAFNESS

The cochlear implant provides hearing information to the severe-profoundly deaf by electrically stimulating the auditory nerves of the inner..

SMART DRUG DELIVERY USING NANOTECHNOLOGY TO PREVENT HEARING LOSS

Hearing loss is a common sensory deficit and can get progressively worse over time, eventually requiring a cochlear implant. In this project..

Grants

Awarded by National Health and Medical Research Council (NHMRC)

Awarded by Australian Research Council under the Australian Laureate Fellowship scheme

Awarded by National Institutes of Health (USA)

Awarded by National Natural Science Foundation of China

Funding Acknowledgements

Y.W. and A.K.W. contributed equally to this work. This work was supported by the National Health and Medical Research Council (NHMRC) Project Grant APP1005071 (R.K.S., F.C., J.T., Y.W., A.K.W) and Project Grant APP1064375 (A.K.W., F.C. and R.K.S.), by the Australian Research Council under the Australian Laureate Fellowship scheme (F.C., 120100030) and the National Institutes of Health (USA) HHS-N-263-2007-00053-C (R.K.S.). The Bionics Institute acknowledges the support it receives from the Victorian government through its Operational Infrastructure Support Program. Y.W. acknowledges support from The National Young 1000 Talents Program of China and the National Natural Science Foundation of China (21373059).